{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:34:53Z","timestamp":1787668493311,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010293","name":"Seagen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020124","name":"Seagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ygyno.2022.07.026","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T08:30:29Z","timestamp":1659169829000},"page":"567-575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real-world treatment drop-off among recurrent or metastatic cervical cancer patients: A US community oncology-based analysis"],"prefix":"10.1016","volume":"166","author":[{"given":"Zachary","family":"Alholm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitong J.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavanya","family":"Sudharshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2022.07.026_bb0005","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.ygyno.2022.07.026_bb0015","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ygyno.2009.06.001","article-title":"Follow-up for women after treatment for cervical cancer: a systematic review","volume":"114","author":"Elit","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.07.026_bb0020","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ygyno.2012.09.008","article-title":"Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study","volume":"127","author":"Alberts","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.07.026_bb0025","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.critrevonc.2016.11.006","article-title":"Management of patients with recurrent\/advanced cervical cancer beyond first line platinum regimens: where do we stand? A literature review","volume":"108","author":"Boussios","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.ygyno.2022.07.026_bb0030","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/COC.0b013e31803377c8","article-title":"Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"30","author":"Garcia","year":"2007","journal-title":"Am. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2022.07.026_bb0035","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ygyno.2012.12.035","article-title":"Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials","volume":"129","author":"Leath","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2022.07.026_bb0040","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/00000421-199610000-00002","article-title":"A phase II trial of 5-fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"19","author":"Look","year":"1996","journal-title":"Am. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2022.07.026_bb0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ygyno.2004.09.027","article-title":"Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the gynecologic oncology group","volume":"96","author":"Schilder","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.07.026_bb0050","author":"NCCN"},{"issue":"20","key":"10.1016\/j.ygyno.2022.07.026_bb0055","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical Cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ygyno.2022.07.026_bb0060","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ygyno.2022.07.026_bb0065","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2022.07.026_bb0070","unstructured":"US Food and Drug Administration. FDA Approves Pembrolizumab for Advanced Cervical Cancer with Disease Progression During or After Chemotherapy. June 13; 2021 https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-advanced-cervical-cancer-disease-progression-during-or-after-chemotherapy. Accessed November, 2021."},{"key":"10.1016\/j.ygyno.2022.07.026_bb0075","author":"US Food"},{"issue":"18","key":"10.1016\/j.ygyno.2022.07.026_bb0080","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s40265-021-01633-8","article-title":"Tisotumab Vedotin: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs."},{"issue":"7","key":"10.1016\/j.ygyno.2022.07.026_bb0085","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/ijgc-2019-001135","article-title":"CALLA: efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study","volume":"30","author":"Mayadev","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2022.07.026_bb0090","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS6096","article-title":"ENGOT-cx11\/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer","volume":"38","author":"Lorusso","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.07.026_bb0095","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ygyno.2021.03.002","article-title":"Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis","volume":"161","author":"Alholm","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"10103","key":"10.1016\/j.ygyno.2022.07.026_bb0105","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (gynecologic oncology group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet."},{"issue":"11","key":"10.1016\/j.ygyno.2022.07.026_bb0110","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1447-0756.2012.01871.x","article-title":"Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation","volume":"38","author":"Kim","year":"2012","journal-title":"J. Obstet. Gynaecol. Res."},{"issue":"1","key":"10.1016\/j.ygyno.2022.07.026_bb0115","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1186\/s12885-021-08243-3","article-title":"Potential prognostic factors in progression-free survival for patients with cervical cancer","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2022.07.026_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030519","article-title":"Brain metastases from uterine cervical and endometrial Cancer","volume":"13","author":"Kato","year":"2021","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ygyno.2022.07.026_bb0125","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.12659\/MSM.912071","article-title":"Real-world study of the incidence, risk factors, and prognostic factors associated with bone metastases in women with uterine cervical cancer using surveillance, epidemiology, and end results (SEER) data analysis","volume":"24","author":"Zhang","year":"2018","journal-title":"Med. Sci. Monitor: Intern. Med. J. Exper. Clin. Res."},{"issue":"1","key":"10.1016\/j.ygyno.2022.07.026_bb0130","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3802\/jgo.2015.26.1.12","article-title":"Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: a retrospective analysis in a Japanese cohort","volume":"26","author":"Endo","year":"2015","journal-title":"J. Gynecol. Oncol."},{"issue":"19","key":"10.1016\/j.ygyno.2022.07.026_bb0135","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1200\/JCO.2014.57.7122","volume":"33","author":"Rose","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.07.026_bb0140","author":"Kassambara"},{"key":"10.1016\/j.ygyno.2022.07.026_bb0145","article-title":"Bevacizumab eligibility in patients with metastatic and recurrent cervical cancer: A retrospective review. Clinical medicine insights","volume":"12","author":"WPT","year":"2018","journal-title":"Oncology."},{"issue":"1\u20132","key":"10.1016\/j.ygyno.2022.07.026_bb0150","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cca.2008.06.017","article-title":"Establishing age\/sex related serum creatinine reference intervals from hospital laboratory data based on different statistical methods","volume":"396","author":"Pottel","year":"2008","journal-title":"Clin. Chim. Acta"},{"issue":"3","key":"10.1016\/j.ygyno.2022.07.026_bb0155","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.clon.2016.10.002","article-title":"The impact of systemic therapy beyond first-line treatment for advanced cervical Cancer","volume":"29","author":"McLachlan","year":"2017","journal-title":"Clin. Oncol. (R Coll. Radiol)."},{"issue":"14","key":"10.1016\/j.ygyno.2022.07.026_bb0160","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010340","article-title":"The combination of cisplatin and topotecan as a second-line treatment for patients with advanced\/recurrent uterine cervix cancer","volume":"97","author":"Moon","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ygyno.2022.07.026_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2021.12.028","article-title":"Trends in treatment patterns and costs of care among patients with advanced stage cervical cancer","author":"Musa","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"20","key":"10.1016\/j.ygyno.2022.07.026_bb0170","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.7150\/jca.46258","article-title":"Risk factors and prognostic predictors for cervical Cancer patients with lung metastasis","volume":"11","author":"Chen","year":"2020","journal-title":"J. Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2022.07.026_bb0175","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s13244-015-0417-x","article-title":"Chemotherapy-related complications in the kidneys and collecting system: an imaging perspective","volume":"6","author":"Jia","year":"2015","journal-title":"Insights Imag."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822005091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822005091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:03:50Z","timestamp":1758773030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825822005091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0090825822005091"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.07.026","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world treatment drop-off among recurrent or metastatic cervical cancer patients: A US community oncology-based analysis","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}